YY1 and non-Hodgkin lymphoma: Therefore, both YY1 and survivin serve a pro-tumorigenic role in aggressive B-NHLs, particularly in B-cell lymphomas (BLs), and survivin is likely a good potential diagnostic and prognostic biomarker for chemotherapy responses in patients with NHL [109].